Loading...
Market
How many additional countries will approve Neffy for use by August 31, 2025?
2
Resolution / Starting Odds
0 countries • 25%
1 to 3 countries • 25%
4 to 6 countries • 25%
More than 6 countries • 25%
Regulatory announcements from health authorities in other countries
Story
FDA Approves Neffy, First Needle-Free Epinephrine Treatment for Anaphylaxis
Aug 9, 2024, 04:52 PM
The U.S. Food and Drug Administration (FDA) has approved a new epinephrine nasal spray, neffy, developed by ARS Pharmaceuticals, as the first needle-free treatment for severe allergic reactions, including anaphylaxis. This approval, announced on Friday, marks a significant advancement in the treatment of allergic emergencies, offering an alternative to traditional epinephrine auto-injectors like the EpiPen. The nasal spray is approved for use in adults and pediatric patients who weigh at least 66 pounds. The FDA's decision is seen as a major step in improving accessibility and ease of use for individuals at risk of life-threatening allergic reactions.
View original story
Similar markets
1-3 countries • 25%
4-6 countries • 25%
7-9 countries • 25%
10 or more countries • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
31 or more countries • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
Less than 5 countries • 25%
5 to 10 countries • 25%
11 to 20 countries • 25%
More than 20 countries • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 20 • 25%
More than 20 • 25%
Less than 5 • 33%
5 to 10 • 34%
More than 10 • 33%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%